Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gemini Therapeutics Inc
(NQ:
GMTX
)
N/A
UNCHANGED
Last Price
Updated: 3:59 PM EST, Dec 29, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Gemini Therapeutics Inc
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Gemini Therapeutics, Inc. (GMTX) Investigation
February 21, 2023
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
GEMINI THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Gemini Therapeutics, Inc. - GMTX
August 12, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
GMTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Merger of Gemini Therapeutics, Inc. Is Fair to Shareholders
August 10, 2022
From
Halper Sadeh LLP
Via
Business Wire
Gemini Therapeutics and Disc Medicine Announce Merger Agreement
August 10, 2022
From
Gemini Therapeutics, Inc.
Via
Business Wire
Gemini Therapeutics Provides Corporate Update
February 28, 2022
From
Gemini Therapeutics, Inc.
Via
Business Wire
Gemini Therapeutics Provides GEM103 Program Update
January 10, 2022
From
Gemini Therapeutics, Inc.
Via
Business Wire
Gemini Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
November 15, 2021
From
Gemini Therapeutics, Inc.
Via
Business Wire
Gemini Therapeutics Announces Poster Presentation at AAO 2021
November 12, 2021
From
Gemini Therapeutics, Inc.
Via
Business Wire
Gemini Therapeutics to Participate in Upcoming Investor Conferences
November 11, 2021
From
Gemini Therapeutics, Inc.
Via
Business Wire
Gemini Therapeutics Announces Presentation at 2nd Annual Dry AMD Therapeutic Development Summit
October 19, 2021
From
Gemini Therapeutics, Inc.
Via
Business Wire
Gemini Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
October 14, 2021
From
Gemini Therapeutics, Inc.
Via
Business Wire
Gemini Therapeutics Announces Corporate Restructuring to Prioritize Late-Stage Clinical Development of GEM103 for Geographic Atrophy
October 05, 2021
From
Gemini Therapeutics, Inc.
Via
Business Wire
Gemini Therapeutics Announces Presentation of Preclinical Data at the 13th International Conference on Complement Therapeutics
September 10, 2021
From
Gemini Therapeutics, Inc.
Via
Business Wire
Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at EURETINA 2021 Virtual
September 09, 2021
From
Gemini Therapeutics, Inc.
Via
Business Wire
Gemini Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021
From
Gemini Therapeutics, Inc.
Via
Business Wire
Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at Clinical Trials at the Summit
August 30, 2021
From
Gemini Therapeutics, Inc.
Via
Business Wire
Gemini Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
August 12, 2021
From
Gemini Therapeutics, Inc.
Via
Business Wire
Gemini Therapeutics to Participate in the H.C. Wainwright Ophthalmology Conference
August 10, 2021
From
Gemini Therapeutics, Inc.
Via
Business Wire
Gemini Therapeutics Announces Initial Data From Its Ongoing Phase 2a Study of GEM103 in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
June 22, 2021
From
Gemini Therapeutics, Inc.
Via
Business Wire
Gemini Therapeutics to Participate in the Jefferies Virtual Healthcare Conference
May 26, 2021
From
Gemini Therapeutics, Inc.
Via
Business Wire
Gemini Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
May 13, 2021
From
Gemini Therapeutics, Inc.
Via
Business Wire
Gemini Therapeutics Completes Enrollment in Phase 2a Study of GEM103 as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMD Patients at Risk for Progressive Vision Loss Due to Macular Atrophy
May 13, 2021
From
Gemini Therapeutics, Inc.
Via
Business Wire
Gemini Therapeutics Announces Appointment of Georges Gemayel, Ph.D. as Chair of Board of Directors
May 03, 2021
From
Gemini Therapeutics, Inc.
Via
Business Wire
Gemini Therapeutics Announces Presentation of Preclinical Data at 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 01, 2021
From
Gemini Therapeutics, Inc.
Via
Business Wire
Gemini Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
April 13, 2021
From
Gemini Therapeutics, Inc.
Via
Business Wire
Gemini Therapeutics Appoints Samuel Barone, M.D., as Chief Medical Officer
April 12, 2021
From
Gemini Therapeutics, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.